
Photo taken from Agenus/LinkedIn
Sep 15, 2024, 00:29
Breelyn Wilky on botensilimab and balstilimab for refractory sarcomas at ESMO24
Agenus shared on LinkedIn:
“Breelyn Wilky, presented new data at ESMO24 highlighting the potential of our investigational immunotherapy combination, botensilimab and balstilimab, for treating patients with refractory sarcomas.
Learn more about this advancement.”
Source: Agenus/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 3, 2025, 17:15
Aug 3, 2025, 17:14
Aug 3, 2025, 17:02
Aug 3, 2025, 16:42
Aug 3, 2025, 16:24
Aug 3, 2025, 16:01
Aug 3, 2025, 15:57